ArticlePolymers2021
Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells.
Article in Polymers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Biodegradable PCL-PLGA Electrospun Nanofibers for Localized Cancer Therapy.ACS applied bio materials · 2026Article
- Fabrication of docetaxel-loaded PEG-modified calcium carbonate-loaded zeolite imidazole nanoframeworks for synergic gastric cancer photothermal therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comprehensive phytochemical profiling of bioactive compounds fromBiochemistry and biophysics reports · 2025Article
- Assessing the anticancer potential of Bergenia ciliata conjugated silk fibroin nanoparticles through histopathological and biomarkers study.Journal of molecular histology · 2025Article
- Green synthesis of silver nanoparticles using cocoon extract of Bombyx mori L.: therapeutic potential in antibacterial, antioxidant, anti-inflammatory, and anti-tumor applications.BMC biotechnology · 2025Article
- Optimized and Functionalized Carvacrol-Loaded Nanostructured Lipid Carriers for Enhanced Cytotoxicity in Breast Cancer Cells.Pharmaceutics · 2025Article
- In-vitro antioxidant and anti-proliferative activity of aerial parts of Senecio Laetus Edgew on breast cancer (MCF-7) and colon carcinoma (HCT116) cell lines.BMC complementary medicine and therapies · 2025Article
- Nanotechnology Platform for the Delivery of Docetaxel and Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer Therapy.Pharmaceutical nanotechnology · 2025Article
- Research Progress of Docetaxel Nano-Drug Delivery System in the Treatment of Breast Cancer.International journal of nanomedicine · 2025Review
- Ciprofloxacin hydrochloride-loaded ocular silk fibroin liposomes: Formulation, characterisation,Heliyon · 2024Article
- Spanlastic-laden nanogel as a plausible platform for dermal delivery of bimatoprost with superior cutaneous deposition and hair regrowth efficiency in androgenic alopecia.International journal of pharmaceutics: X · 2024Article
- Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches.Journal of translational medicine · 2024Review
- A common molecular and cellular pathway in developing Alzheimer and cancer.Biochemistry and biophysics reports · 2024Review
- Ophthalmic Bimatoprost-Loaded Niosomal In Situ Gel: Preparation, Optimization, and In Vivo Pharmacodynamics Study.Polymers · 2023Article
- Sericultural By-Products: The Potential for Alternative Therapy in Cancer Drug Design.Molecules (Basel, Switzerland) · 2023Review
- Highly Biocompatible Apigenin-Loaded Silk Fibroin Nanospheres: Preparation, Characterization, and Anti-Breast-Cancer Activity.Polymers · 2022Article
- Promising Role of Silk-Based Biomaterials for Ocular-Based Drug Delivery and Tissue Engineering.Polymers · 2022Review
- Silk Fibroin as an Efficient Biomaterial for Drug Delivery, Gene Therapy, and Wound Healing.International journal of molecular sciences · 2022Review
- Article
- Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite decades of research, breast cancer therapy remains a great challenge. Docetaxel is an antimicrotubule agent that is effectively used for the treatment of breast cancer. However, its clinical use is significantly hampered by its low water solubility and systemic toxicity. The current study was designed to prepare docetaxel (DXL)-loaded silk-fibroin-based nanoparticles (SF-NPs) and to screen their potential antitumor activity against breast cancer cell lines. DXL-loaded SF-NPs were prepared using a nanoprecipitation technique and were evaluated for particle size, zeta potential, entrapment efficiency, and in vitro release profile. In addition, DXL-loaded SF-NPs were screened for in vitro cytotoxicity, cellular uptake, and apoptotic potential against MCF-7 and MDA-MB-231 breast cancer cell lines. The prepared DXL-loaded SF-NPs were 178 to 198 nm in diameter with a net negative surface charge and entrapment efficiency ranging from 56% to 72%. In vitro release studies exhibited a biphasic release profile of DXL from SF-NPs with sustained drug release for 72 h. In vitro cell studies revealed that entrapment of DXL within SF-NPs significantly improved cytotoxic potential against breast cancer cell lines, compared to the free drug, and enhanced cellular uptake of DXL by breast cancer cells. Furthermore, the accumulation in the G2/M phase was significantly higher in cells treated with DXL-loaded SF-NPs than in cells treated with free DXL. Collectively, the superior antitumor activities of DXL-loaded SF-NPs against breast cancer cells, compared to free DXL, could be ascribed to improved apoptosis and cell cycle arrest. Our results highlighted the feasibility of using silk fibroin nanoparticles as a nontoxic biocompatible delivery vehicle for enhanced therapeutic outcomes in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.